Validation of the <scp>MASK</scp>‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

Caimmi, Davide; Baïz, Nour; Tanno, Luciana Kase; Demoly, Pascal; Arnavielhe, Sylvie; Murray, Ruth; Bedbrook, Anna; Bergmann, Karl‐Christian; Vries, G. De; Fokkens, Wytske J.; Fonseca, João; Haahtela, Tari; Keil, Thomas; Kuna, Piotr; Mullol, Joaquim; Papadopoulos, Nikos; Passalacqua, Giovanni; Samoliński, Bolesław; Tomazic, PV; Valiulis, Arūnas; Eerd, M. van; Wickman, Magnus; Annesi-Maesano, I.; Bousquet, Jean

doi:10.1111/cea.13025

Cited by 78 publications

(78 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a previous study, it was found that the correlation between VAS global measured and VAS nose increased from ρ = .76 for day 1 to ρ = .83 for all days . Moreover, this was also confirmed in the validation study …”

Section: Methodssupporting

confidence: 70%

See 1 more Smart Citation

Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study

Bousquet¹,

Devillier²,

Antó³

et al. 2018

Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodssupporting

confidence: 70%

“…A mobile phone app ( Allergy Diary ) central to MASK is available in 22 countries. It has been validated and was found to be an easy and effective method of assessing symptoms of AR using visual analogue scales (VAS) and work productivity …”

Section: Introductionmentioning

confidence: 99%

Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study

Bousquet¹,

Devillier²,

Antó³

et al. 2018

Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ARIA guideline proposes a classification of AR based on symptom control, QOL, and daily impact as well as duration . Disease control associated with several health outcomes, including QOL and some mHealth end points, should be considered in ICPs. Although the duration of rhinitis is an important indicator of asthma multimorbidity, and duration and efficacy of treatment in AR, AR control should be considered as the most important end point for the pharmacist.…”

Section: Management Of Allergic Rhinitis In the Pharmacy: Aria‐pharmamentioning

confidence: 99%

“…VAS can be used to assess overall AR control (VAS global measure) as it relates to nasal symptoms and eye symptoms (Figures ,6). There is a high degree of correlation between VAS global measured (“Overall how much are your allergic symptoms bothering you today?”) and VAS for nose symptoms . An electronic form of the VAS exists in the Allergy Diary and has been validated against several end points.…”

Section: Management Of Allergic Rhinitis In the Pharmacy: Aria‐pharmamentioning

confidence: 99%

“…The Allergy Diary (MASK‐rhinitis) has been implemented in 23 countries and 16 languages. Over 23 000 users have been recorded . This tool appears to be appropriate for pharmacists, in particular since it is extremely simple, does not require the pharmacist to undertake any particular education on its use, is user‐friendly for the patient, and can be used for follow‐up over time.…”

Section: Management Of Allergic Rhinitis In the Pharmacy: Aria‐pharmamentioning

confidence: 99%

See 1 more Smart Citation

ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”

Bosnic‐Anticevich

Costa

Menditto

et al. 2019

Allergy

View full text Add to dashboard Cite

Pharmacists are trusted health care professionals. Many patients use over‐the‐counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)‐pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA‐pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care.

show abstract

Correlation of the combined symptom and medication score with quality of life, symptom severity and symptom control in allergic rhinoconjunctivitis

Palathumpattu

Pieper‐Fürst²,

Açıkel³

et al. 2022

Clinical & Translational All

View full text Add to dashboard Cite

Background The European Academy of Allergy and Clinical Immunology recommended the Combined Symptom and Medication Score (CSMS) as primary endpoint in clinical trials on allergen‐specific immunotherapy (AIT) in allergic rhinoconjunctivitis. Here, the correlation between the CSMS and the validated standardised Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)), Rhinitis Control Assessment Test (RCAT) and Visual Analogue Scale (VAS) was analysed. Methods Two prospective, multicentre, non‐interventional studies on tree pollen, grass pollen and house dust mite allergic patients were performed. The first study comprised 167 patients receiving AIT (AIT population), and the second included 56 patients treated with symptomatic medication only (control population). For up to two seasons (pollen)/exposure periods (house dust mites), participants documented their symptoms and medication intake in a CSMS diary, including VAS. In addition, the standardised RQLQ(S) and the RCAT were completed during study visits. Results Comparison between CSMS and RQLQ(S) revealed a positive correlation in the AIT population ( r = 0.426) and in the control population ( r = 0.569). For CSMS and RCAT, a negative correlation with r = −0.409 (AIT) and r = −0.547 (control) was shown. Positive correlation between CSMS and VAS was also demonstrated with r = 0.585 (AIT) and r = 0.563 (control). Conclusion These results support the assumption that the CSMS correlates with quality of life, symptom severity and symptom control on the one hand, while the moderate strength of correlations on the other hand mirrors distinctions of the CSMS compared to the assessments used here.

show abstract

Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

Abstract: The MASK-rhinitis VAS is a reliable and valid tool to assess allergic control on smartphone screens, at the population level.

Cited by 78 publications

References 24 publications

Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study

Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study

ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”

Correlation of the combined symptom and medication score with quality of life, symptom severity and symptom control in allergic rhinoconjunctivitis

Contact Info

Product

Resources

About